Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 65,585 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,148,000.

Other institutional investors also recently modified their holdings of the company. Raiffeisen Bank International AG bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. bought a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $30,000. Versant Capital Management Inc grew its position in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 1,109 shares during the period. GF Fund Management CO. LTD. bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $42,000. Finally, Headlands Technologies LLC grew its position in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,015 shares during the period.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $33.56 on Thursday. Supernus Pharmaceuticals, Inc. has a one year low of $27.05 and a one year high of $40.28. The company’s fifty day moving average price is $32.51 and its 200-day moving average price is $33.43. The company has a market capitalization of $1.88 billion, a PE ratio of 30.23 and a beta of 0.70.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SUPN shares. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 20th. Cantor Fitzgerald raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $42.00 price target on the stock in a report on Wednesday.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.